Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases

Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market to Reach US$16.4 Billion by 2030

The global market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases estimated at US$9.9 Billion in the year 2024, is expected to reach US$16.4 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030.

The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 8.3% CAGR

The Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market in the U.S. is estimated at US$2.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Neurological Biomarkers Market for Alzheimer’s and Parkinson’s Diseases - Key Trends & Drivers Summarized

What Are Neurological Biomarkers and Why Are They Crucial for Alzheimer’s and Parkinson’s Diseases?
Neurological biomarkers are biological indicators found in the blood, cerebrospinal fluid (CSF), or other tissues that can signal the presence or progression of neurological diseases, particularly Alzheimer’s and Parkinson’s. These biomarkers are critical for diagnosing these conditions, monitoring their progression, and evaluating the efficacy of treatments. In the case of Alzheimer’s disease, common biomarkers include amyloid-beta plaques and tau proteins, which accumulate in the brain and disrupt normal function. For Parkinson’s disease, biomarkers often involve alpha-synuclein, a protein associated with the loss of dopamine-producing neurons.

The importance of neurological biomarkers in Alzheimer`s and Parkinson’s diseases cannot be overstated, as early and accurate diagnosis is essential for managing these progressive disorders. Biomarkers not only help detect these diseases before severe symptoms manifest but also aid in the development of personalized treatments that target specific pathways. As research continues to advance, biomarkers are becoming a key focus in efforts to slow or prevent the onset of these debilitating conditions.

How Are Neurological Biomarkers Revolutionizing Diagnosis and Treatment?
The field of neurological biomarkers is revolutionizing the way Alzheimer’s and Parkinson’s diseases are diagnosed and treated. One of the most significant trends is the development of non-invasive biomarker tests, such as blood-based assays, that can detect early signs of Alzheimer’s and Parkinson’s with greater convenience and lower cost compared to traditional methods like lumbar punctures or brain imaging. These non-invasive tests have the potential to become widely used screening tools, allowing for earlier intervention and better management of these diseases.

Furthermore, biomarkers are being used to track disease progression, which is essential for both clinical research and patient care. This capability is particularly valuable in the development of disease-modifying therapies, as it provides a way to measure the effectiveness of treatments in real-time. Advances in neuroimaging biomarkers, such as positron emission tomography (PET) scans for amyloid and tau detection, are also playing a crucial role in refining diagnoses and enabling more targeted interventions.

What Are the Applications of Neurological Biomarkers in Alzheimer’s and Parkinson’s Research?
Neurological biomarkers are driving significant advancements in Alzheimer’s and Parkinson’s research, particularly in the areas of drug development and personalized medicine. In clinical trials for Alzheimer’s, biomarkers are used to identify patients who are most likely to benefit from experimental treatments, improving the chances of success for new therapies. Biomarkers also help stratify patient populations, allowing researchers to study the effects of drugs on specific disease stages or subtypes, which can lead to more effective treatments tailored to individual needs.

For Parkinson’s disease, biomarkers are critical for understanding the underlying mechanisms of the disease and identifying new therapeutic targets. The ability to track the progression of Parkinson’s through biomarkers such as alpha-synuclein levels or neuroinflammation markers enables researchers to develop treatments aimed at halting or slowing the degenerative process. Additionally, biomarkers are being integrated into clinical care, where they assist physicians in making more informed decisions about treatment strategies, particularly in distinguishing between different forms of dementia or parkinsonian syndromes.

What Are the Key Growth Drivers in the Neurological Biomarkers Market?
The growth in the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases is driven by several factors. First, the increasing prevalence of neurodegenerative diseases, particularly in aging populations, is a major driver, as early diagnosis and treatment become more urgent. Second, the shift towards precision medicine is fueling demand for biomarkers that can guide personalized treatment plans based on an individual’s unique disease profile. Advances in biomarker detection technologies, such as liquid biopsy and next-generation sequencing, are also accelerating the adoption of these tools in both research and clinical settings.

The expanding focus on disease-modifying therapies for Alzheimer’s and Parkinson’s is another key growth driver. As pharmaceutical companies invest heavily in developing new drugs, biomarkers are essential for identifying the right patient populations and measuring therapeutic efficacy. Regulatory agencies, including the FDA, are increasingly supporting the use of biomarkers in drug development, providing incentives for continued innovation in this space. Additionally, public and private funding for neurological research is on the rise, creating a favorable environment for biomarker discovery and commercialization.

SCOPE OF STUDY:

The report analyzes the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Segment (Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

• AbaStar MDx
• Abbott Laboratories
• Abiant
• Acumen Pharmaceuticals
• Alseres Pharmaceuticals
• Athena Diagnostics
• Athena Diagnostics
• Banyan Biomarkers
• Bio-Rad Laboratories
• Diagenic ASA
• Immunarray Pvt. Ltd.
• Myriad RBM
• Proteome Sciences
• ProteoSys AG
• Psynova Neurotech
• Qiagen
• Quanterix Corporation
• Thermo Fisher Scientific

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.